EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Targeting CCL24 in Inflammatory and Fibrotic Diseases: Rationale and Results from Three CM-101 Phase 1 Studies

Adi Mor, Scott Friedman, Sharon Hashmueli, Amnon Peled, Massimo Pinzani, Matthew Frankel, Rifaat Safadi

Drug Safety · 2024-09 · 47 (9) · 869-881

DOI: 10.1007/s40264-024-01436-2 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Drug Safety, online erschienen am 01.06.2024. Verfasst von Adi Mor und 6 weiteren Autor:innen. Beteiligte Einrichtung: Chemomab Therapeutics, Kiryat Atidim, Building 7, 6158002, Tel Aviv, Israel. adimor@chemomab.com. Hauptthemen laut MEDLINE: Chemokine CCL24, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chemokine CCL24Antibodies, Monoclonal, HumanizedHumansDouble-Blind MethodMaleFemaleAdultMiddle AgedInjections, SubcutaneousDose-Response Relationship, DrugInflammationYoung AdultFibrosisAgedFatty Liver

Substanzen

Chemokine CCL24Antibodies, Monoclonal, HumanizedCCL24 protein, human

Autor:innen und Institutionen

  • Chemomab Therapeutics, Kiryat Atidim, Building 7, 6158002, Tel Aviv, Israel. adimor@chemomab.com.
  • Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Chemomab Therapeutics, Kiryat Atidim, Building 7, 6158002, Tel Aviv, Israel.
  • Goldyne Savad Institute of Gene Therapy, Hebrew University Hospital, Jerusalem, Israel.
  • UCL Institute for Liver and Digestive Health, University College of London, Royal Free Hospital, London, UK.
  • Sheila Sherlock Liver Centre, Royal Free London NHS Foundation Trust, London, UK.

Zitieren

APA

Mor, A., Friedman, S., Hashmueli, S., Peled, A., Pinzani, M., Frankel, M., & Safadi, R. (2024). Targeting CCL24 in Inflammatory and Fibrotic Diseases: Rationale and Results from Three CM-101 Phase 1 Studies. Drug Safety, 47(9), 869-881. https://doi.org/10.1007/s40264-024-01436-2

Vancouver

Mor A, Friedman S, Hashmueli S, Peled A, Pinzani M, Frankel M, et al. Targeting CCL24 in Inflammatory and Fibrotic Diseases: Rationale and Results from Three CM-101 Phase 1 Studies. Drug Safety. 2024;47(9):869-881. doi:10.1007/s40264-024-01436-2

BibTeX
@article{Mor2024,
  author = {Mor, Adi and Friedman, Scott and Hashmueli, Sharon and Peled, Amnon and Pinzani, Massimo and Frankel, Matthew and Safadi, Rifaat},
  title = {Targeting CCL24 in Inflammatory and Fibrotic Diseases: Rationale and Results from Three CM-101 Phase 1 Studies},
  journal = {Drug Safety},
  year = {2024},
  volume = {47},
  number = {9},
  pages = {869--881},
  doi = {10.1007/s40264-024-01436-2}
}
Kostenlos starten →